LIS Technologies Inc is IPO-ing. The Oak Ridge, TN company is developing CRISLA, a patented laser uranium enrichment process it calls the only U.S.-origin one. Headline metric: $6.00 midpoint price ra

Pre-revenue and pre-commercial: CRISLA sits at TRL-4, roughly 75% of the way to TRL-5. The company has raised about $64M across four oversubscribed rounds and bought a $6.2M facility next to its test site on the former K-25 site. Risks are front and center: speculative, early-stage with limited operating history, dilution, and dependence on offering proceeds to fund operations. Net proceeds of ~$15.1M ($17.5M with full over-allotment) go to general corporate purposes. The tailwind is real: DOE selected LIS alongside NANO Nuclear under a reported $34B LEU enrichment program, and SMRs need 5-19.75% enriched fuel traditionally supplied by Russia. But incumbents like Urenco and Orano dominate, and LIS is pre-commercial. Bottom line: a policy-tailwind story with a $1B facility plan but no revenue, no disclosed product detail in the filing, and a small ~$15M raise. Speculative bet on U.S. enrichment capacity — size positions accordingly.

Pre-revenue and pre-commercial: CRISLA sits at TRL-4, roughly 75% of the way to TRL-5. The company has raised about $64M across four oversubscribed rounds and bought a $6.2M facility next to its test